Keywords: osi, 55m, deal, sell, serono, novantrone, pharmaceuticals
OSI in $55M deal to sell Serono's Novantrone
Article | 17 March 2003
OSI Pharmaceuticals has entered into an agreement to market Serono'santicancer drug Novantrone (mitoxantrone concentrate for injection) in the USA in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
